Diagnostica Stago SAS - proposed acquisition of Trinity Biotech's haemostasis business
Type of assessment
Informal Review
Reference
40957
Acquirer(s)
Diagnostica Stago SAS
Target(s)
Trinity Biotech's haemostasis business
Industry
Haemostasis reagents and instruments
Summary
Diagnostica Stago SAS - proposed acquisition of Trinity Biotech's haemostasis business
Outcome of assessment
Not opposed
Total review days *
14
Commenced public review
15th March 2010
Date completed
1st April 2010
Market definition
It was not considered necessary to form a definitive view on the relevant market definition. However, the acquisition was considered in relation to the Australian market for haemostasis reagents and instruments.
Competition analysis
It was considered that the proposed acquisition would be unlikely to result in a substantial lessening of competition in any market, including because it appears:
- the merged firm is likely to continue to face strong competition from substitute suppliers, notably Siemens Healthcare Diagnostics and Beckman Coulter; and
- the proposed acquisition is unlikely to result in the removal of a vigorous and effective competitor.
Review timeline
Date
Event
15th March 2010
ACCC commenced a review under the Merger Review Process Guidelines.
26th March 2010
Closing date for submissions from interested parties.
1st April 2010
ACCC announced it would not oppose the proposed acquisition.
* Total Review days = Total business days less public holidays and time during which the review was suspended.
